Fig. 1 · Structure

Documents & Downloads

IKK-16

Cat. No. A12836 CAS 873225-46-8

IKK Inhibitor

IKK 16 is a selective IκB kinase (IKK) inhibitor for IKK-2, IKK complex and IKK-1 with IC50 of 40 nM, 70 nM and 200 nM, respectively.

In Stock

Publications for IKK-16

1 publication citing this product

  1. Rulina AV, .et al. , Cell Death Dis, 2016, Dec 1;7(12):e2505 PMID: 27906189

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

IKK-16 treatment attenuated IKK/IκBα phosphorylation and nuclear NF-κB p65 accumulation in kidney and liver from rats with hemorrhagic shock. Its effects require cautious target attribution: separate biochemical experiments showed inhibition of PKCα, PKCδ and CAMKIIα at micromolar concentrations. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
IKK2 (Cell-free assay) 40 nM
IKK complex (Cell-free assay) 70 nM
IKK1 (Cell-free assay) 200 nM

Cellular Effect

Cell Line Activity Value Description Reference
HEK293 EC50 0.003 μM Inhibition of atypical PKCzeta in HEK293 cells assessed as TNF-induced NFkappaB activation incubated for 3 hrs prior to TNF induction measured after 5 hrs by bright-glo luciferase reporter gene assay [PMID: 23566515]

IKK-16 Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of IKK-16 from 3 published references. In vitro models include recombinant PKCα, PKCδ and CAMKIIα in radiometric kinase assays.

IKK-16 In Vitro Studies

In VCaP prostate cancer cells, 2 μM IKK16 reduced apoptosis induced by 500 nM MLN4924 during a 5-day combination treatment. This protective interaction illustrates that IKK16 responses depend on the treatment context. [3]

IKK16 reduces MLN4924-induced VCaP apoptosis

Cell-based study · Human VCaP prostate cancer cells in medium supplemented with 10% charcoal-stripped serum. [3]

IKK16 at 2 μM reduced apoptosis induced by 500 nM MLN4924 over 5 days. The result is a combination-dependent protective response in this model, not evidence of IKK16 monotherapy killing.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Fraction of cells scored apoptotic by caspase-3/7 signalqualitative response IKK16 reduced the MLN4924-induced apoptotic fraction at 500 nM MLN4924 versus MLN4924 without IKK16.[3]

Literature-Reported Treatment Conditions

Treatment concentration
IKK16 2 μM; MLN4924 0, 50 or 500 nM in Figure 5c.
Exposure duration
5 days
Method
Cell treatment; caspase-3/7 CellEvent fluorescence with Hoechst-based nuclear segmentation.
Vehicle
0.5% DMSO final; 0.5% DMSO control in SI Chemical inhibitor screening.
Co-treatment
MLN4924 (MLN), especially 500 nM for the stated apoptosis reduction.
Reported limits
Independent biological experiment count for Figure 5c is not specified in the located figure/methods. SI general data quantification mentions four well replicates, whereas chemical inhibitor screening states triplicates; neither is relabeled biological n.
Methods and source locations

Compound reported in the paper: IKK-16; Compound label in the paper: IKK16

Research findings for the material identified as IKK-16 in this publication; no A12836 lot validation or salt-equivalence claim.

Results: CRL inhibition globally affects cell signaling and transcription; Figure 5c and caption; main Apoptosis assay; SI pp. 2–4, 7 and Table S5 p. 28.

Fraction of cells scored apoptotic by caspase-3/7 signal: CellEvent Caspase-3/7 Green reagent and Hoechst segmentation; boxplots. SI statistical section specifies two-sided Wilcoxon rank-based test. Exact fractions are not inferred from the plot. — Figure 5c and caption; Results CRL inhibition globally affects cell signaling and transcription; SI Apoptosis assay, Data quantification and Chemical inhibitor screening.

Kinase selectivity limits of IKK-16

Biochemical assay · Recombinant PKCα, PKCδ and CAMKIIα in radiometric kinase assays. [2]

IKK-16 inhibited PKCα, PKCδ and CAMKIIα in the micromolar range, demonstrating limits to assigning a cellular response exclusively to IKK inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PKCα and PKCδ activityqualitative response Concentration-dependent inhibition; >50% inhibition at 10 μM as stated in Results.[2]
CAMKIIα activityqualitative response Concentration-dependent inhibition, with activity nearly abolished at 10 μM.[2]

Literature-Reported Treatment Conditions

Treatment concentration
Figure 3A–B: 10 nM, 100 nM, 1 μM and 10 μM; Figure 3C: 100 nM, 1 μM and 10 μM.
Exposure duration
10 min kinase reaction at 30°C.
Method
Radiometric substrate phosphorylation assay.
Vehicle
DMSO comparator; final vehicle percentage not specified in the located methods.
Co-treatment
None; 1-NA-PP1 comparator and GF109203X positive control for PKC assays.
Reported limits
Salt/form and lot absent; no cellular IKK-selectivity conclusion follows from this biochemical panel.
Methods and source locations

Compound reported in the paper: IKK-16; Compound label in the paper: IKK-16

Research findings for the material identified as IKK-16 in this publication; no A12836 lot validation or salt-equivalence claim.

Results: 1-NA-PP1 is an ATP-competitive inhibitor with high selectivity for PKD over closely related kinases; Figure 3A–C and caption; Chemicals and Reagents; In Vitro Radiometric PKC and CAMKIIα Kinase Assay.

PKCα and PKCδ activity: Radiometric assay using myelin basic protein substrate; DMSO baseline; GF109203X positive control. Figure 3 caption: mean ± SEM of two independent experiments. — Figure 3A–B and caption; Results kinase-specificity paragraph; In Vitro Radiometric PKC and CAMKIIα Kinase Assay.

CAMKIIα activity: Radiometric assay using syntide-2; DMSO comparator; 1-NA-PP1 had little activity up to 10 μM. Caption: experiment repeated twice; representative graph shown. — Figure 3C and caption; Results kinase-specificity paragraph; In Vitro Radiometric PKC and CAMKIIα Kinase Assay.

IKK-16 In Vivo Studies

In a rat hemorrhagic-shock model, IKK16 (1 mg/kg intravenously at resuscitation) reduced renal dysfunction, liver and pancreatic injury markers, and lactate at 4 h. Creatine kinase elevation was not significantly reduced. These acute findings do not establish a survival benefit. [1]

IKK16 in rat hemorrhagic shock

Animal study · Male Wistar rats, 230–280 g; hemorrhagic shock and resuscitation; sham-operated controls. [1]

A single IKK16 treatment at resuscitation reduced several organ injury markers and kidney/liver NF-kappaB pathway activation at 4 h. Creatine kinase elevation was not significantly reduced. This was an acute endpoint experiment, not a survival-efficacy study.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Renal function, serum AST/ALT, amylase/lipase, lactate and creatine kinasequalitative response Renal dysfunction, liver/pancreatic injury markers and lactate were significantly attenuated versus shock + vehicle; creatine kinase was not significantly attenuated. Sham + IKK16 showed no significant change in evaluated biochemical markers.[1]
Kidney and liver phospho-IKKαβ, phospho-IκBα and nuclear/cytosolic p65qualitative response IKK16 attenuated shock-associated increases in IKKαβ Ser176/180 phosphorylation, IκBα Ser32/36 phosphorylation and nuclear p65 translocation.[1]

Conditions shared by the study groups

Route
Intravenous
Frequency
Once, at resuscitation
Treatment course
4 h follow-up
Vehicle
10% DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Hemorrhagic shock + IKK16
1 mg/kg
Shock + vehicle; sham + vehicle and sham + IKK16. Random allocation: Sham + Vehicle n = 9, Sham + IKK16 n = 8, HS + Vehicle n = 11, HS + IKK16 n = 11. Endpoint n denotes surviving animals.Reduced renal dysfunction, liver/pancreatic injury markers and lactate; no significant reduction in creatine kinase; attenuated kidney/liver NF-kappaB pathway activation.[1]
Hemorrhagic shock + IKK16
Model: Male Wistar rats subjected to hemorrhagic shock and resuscitation.
Reported limits: No demonstrated long-term survival outcome, exposure measurement, or Adooq lot/form equivalence.
Methods and source locations

Compound reported in the paper: IKK-16; Compound label in the paper: IKK16

Research findings for the material identified as IKK-16 in this publication; no A12836 lot validation or salt-equivalence claim.

Methods: Hemorrhagic Shock Model and Organ Injury Assessment, Experimental Design, Western Blot Analysis, Reagents, Data Analysis; Results: Effects of IKK16 Treatment on HS and on NF-kappaB Pathway; Figures 2 and 5.

Renal function, serum AST/ALT, amylase/lipase, lactate and creatine kinase: Serum biochemistry and estimated creatinine clearance; box-and-whisker minimum to maximum with median, n = 8–11 animals per group; one-way ANOVA with Bonferroni post hoc test; p < 0.05 threshold. No graph-derived numerical means. — Results: Effects of IKK16 Treatment on HS; Figure 2A–H and caption; Data Analysis.

Kidney and liver phospho-IKKαβ, phospho-IκBα and nuclear/cytosolic p65: Western blotting; n = 3–4 animals per group; box-and-whisker minimum to maximum with median; p < 0.05 versus shock as indicated. Read as pathway-associated changes, not direct binding or target-exclusive causality. — Results: Effects of IKK16 Treatment on NF-kappaB Pathway; Figure 5A–F and caption; Western Blot Analysis.

Hemorrhagic shock + IKK16 · Methods: Hemorrhagic Shock Model and Organ Injury Assessment, Experimental Design, Western Blot Analysis, Reagents, Data Analysis; Results: Effects of IKK16 Treatment on HS and on NF-kappaB Pathway; Figures 2 and 5.

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 873225-46-8
Applications IKK Inhibitor
Formula C28H29N5OS
Molecular Weight 483.63
SMILES
C1CCN(C1)C2CCN(CC2)C(=O)C3=CC=C(C=C3)NC4=NC=CC(=N4)C5=CC6=CC=CC=C6S5

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 95 mg/mL (196.42 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
30% PEG400+0.5% Tween80+5% propylene glycol

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

IKK-16 Research References

  1. [1] Sordi R, Chiazza F, Johnson FL, et al. Inhibition of IκB Kinase Attenuates the Organ Injury and Dysfunction Associated with Hemorrhagic Shock. Molecular medicine (Cambridge, Mass.) (2015). PMID: 26101953 DOI: 10.2119/molmed.2015.00049 Source material
  2. [2] Tandon M, Johnson J, Li Z, et al. New pyrazolopyrimidine inhibitors of protein kinase d as potent anticancer agents for prostate cancer cells. PloS one (2013). PMID: 24086585 DOI: 10.1371/journal.pone.0075601 Source material
  3. [3] Rulina AV, Mittler F, Obeid P, et al. Distinct outcomes of CRL-Nedd8 pathway inhibition reveal cancer cell plasticity. Cell death & disease (2016). PMID: 27906189 DOI: 10.1038/cddis.2016.395 Source material

Publications

1 publication citing this product

  1. Rulina AV, .et al. , Cell Death Dis, 2016, Dec 1;7(12):e2505 PMID: 27906189

Added to your cart

View Cart Checkout
Loading...